1-Methyl-5-p-tolyl-1H-pyrazole-3-carboxylic acid, 95.0%, 1g

(S)-2-((tert-Butoxycarbonyl)amino)-2-(2-(trifluoromethyl)phenyl)acetic acid, 98%, 250mg

Naphthalene-1,4,5,8-tetracarboxylic acid, contains Monoanhydride, 60.0%, 25g

Methyl 5-bromo-4-fluorothiophene-2-carboxylate, 97%, 100mg

3-iodo-1-methyl-indazole-5-carbonitrile, 97, 100mg

1-((5,6,7,8-Tetrahydronaphthalen-2-yl)sulfonyl)piperidine-4-carboxylic acid, 100mg

(1r)-1-(3-Bromo-4-fluorophenyl)ethan-1-ol, 97%, 250mg

3-(Methylthio)-5-nitropyridine, 95+%, 1g

2-Bromo-6-methylbenzaldehyde, 97%, 5g

N,N-Dimethyl-1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)methanamine, 95.0%, 25g

2-(isocyanatomethyl)thiophene, 95.0%, 250mg

GC capillary column ROTI®Cap-FFAP, 25 m, 0.32 mm, 0.50 µm, 1 Piece(s)

4-cyclopropyl-1-(3,4-dimethylphenyl)-1,6-dihydro-7H-pyrazolo[3,4-d]pyridazin-7-one, 95.0%, 500mg